FeNO threshold used to select severe asthma patients for Dupilumab may be inappropriate> Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021
GOLD BCD or 234 classifications: Which one better reflects COPD patients' functionality? Source: International Congress 2014 – Physical activity, exercise and physiotherapy in patients with COPD Year: 2014
Is high level of IgE an additional problem in smoking patients with severe and very severe chronic obstructive pulmonary disease (COPD)? Source: Annual Congress 2012 - COPD: epidemiology and varia Year: 2012
Heterogeneity inside group D COPD patients: About 827 cases Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016
The maximum % fall in FEV1 after a mannitol challenge in subjects with asthma, suspected asthma, COPD and bronchiectasis Source: Annual Congress 2010 - Cough, airway hyperresponsiveness and asthma control Year: 2010
The 'surprise question' in patients surviving severe COPD exacerbation. Source: Virtual Congress 2020 – Diagnosis and management of COPD Year: 2020
What clinical features underlying GINA step 1-4 drive the level of treatment in patients with asthma Source: Eur Respir J 2001; 18: Suppl. 33, 57s Year: 2001
Can seriousness of respiratory failure be predicted by the values of clinical score in patients with acute severe asthma? Source: Eur Respir J 2001; 18: Suppl. 33, 73s Year: 2001
Statistical analysis of anthropometric differences between COPD stages 1 and 2 Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016
FEV1 decline in patients with chronic obstructive pulmonary disease: Which treatment option is better for slowing of decline? Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015
COPD (confusion over proper diagnosis) in the zone of maximum uncertainty Source: Eur Respir J 2015; 46: 1525-1526 Year: 2015
COPD (confusion over proper diagnosis) in the zone of maximum uncertainty Source: Eur Respir J 2015; 46: 1523-1524 Year: 2015
Number needed to treat (NNT) to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019
The serum level of surfactantproteind in patients with chronic obstructive pulmonary disease, depending on the nutrtional status Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015
The decrease of nutritional status and increasing of the risk of osteoporotic fractures in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –COPD biomarkers Year: 2013
Proportion and impact of anemia in COPD patients Source: Annual Congress 2010 - COPD: comorbidities Year: 2010
Difficulty in management of COPD exacerbation: Is this chronic exacerbation or difficult COPD: “A specific phenotype?” Source: Annual Congress 2013 –COPD biomarkers Year: 2013